In preclinical studies, PARP inhibitors upregulated the programmed cell death 1 ligand 1 (PD-L1) expression and enhanced the tumor-associated immunosuppression, but PARP inhibitors when combined with anti-PD-L1 therapy were more effective (55). The gene discussed is PARP1; the disease is neoplasm.